Non-Hodgkin's Lymphoma
Conditions
Keywords
pixantrone, NHL, rituximab, fludarabine
Brief summary
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and reduced delayed cardiotoxicity in animal models compared to reference standards. This cytotoxic agent has structural similarities to mitoxantrone as well as general similarities to anthracyclines (such as the tricyclic central quinoid chromophore7). This phase III study will compare the efficacy and safety of the combination BBR 2778, fludarabine, and rituximab with the combination fludarabine and rituximab in patients with relapsed or refractory indolent non-Hodgkin's lymphoma.
Interventions
DRUGfludarabine and rituximab
days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
DRUGfludarabine, rituximab, pixantrone
days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
Sponsors
CTI BioPharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed relapsed or refractory indolent non-Hodgkin's lymphoma (NHL) 2. Any stage (Ann Arbor staging, Appendix 15.7), with or without B symptoms 3. CD 20+ lymphoma (confirmed by immunochemistry) 4. Measurable disease. 5. Atleast 1 prior therapy. 6. Age ≥ 18 years 7. Life expectancy of at least 3 months 8. ECOG performance status (PS) of 0 or 1 9. Adequate cardiac function defined as LVEF ≥ 50% by MUGA scan 10. Adequate renal function 11. Adequate hepatic function 12. Adequate bone marrow function 13. Recovery from all acute toxicities from prior therapies (except alopecia and grade 1 peripheral neuropathy).
Exclusion criteria
1. Prior treatment with a cumulative dose of doxorubicin equivalent exceeding 450 mg/m2 2. Radiotherapy, chemotherapy or other therapies for NHL within 4 weeks of treatment start 3. Systemic corticosteroids to treat NHL within 5 days prior to first dose of study treatment. 4. Radioimmunotherapy (RIT) within 3 months of treatment start 5. Known hypersensitivity to the excipients or the study drugs that the patient will receive 6. Known Type I hypersensitivity or anaphylactic reactions to murine proteins or to any component of rituximab 7. Major thoracic and/or abdominal surgery in the preceding 4 weeks, from which the patient has not fully recovered (patients who have had minor surgery and one week's recovery period may be enrolled) 8. HIV-related lymphoma 9. Active CNS involvement 10. Clinically significant cardiovascular abnormalities 11. Serious (NCI CTCAE grade 3-4) intercurrent infection at randomization, infection requiring oral antibiotics, or deep-seated or systemic mycotic infections. 12. Investigational study drug within 30 days before randomization. Patient must have recovered from all side effects of other investigational therapy. 13. Clinical symptoms suggesting unresolved HIV, HBV or HCV infection. . 14. History of another malignancy except: curatively treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in remission, or any other cancer from which the patient has been disease-free for 5 years 15. Pregnant or lactating women 16. Potentially fertile men and women and their sexual partners not willing to use adequate contraception as defined by the Investigator during the study and for 6 months after the last day of study drug administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival | day 64-71 |
Secondary
| Measure | Time frame |
|---|---|
| response rate, survival, safety | every 21 days |
Countries
United States
Outcome results
None listed